• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • français 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ouvrir une session
Voir le document 
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
JavaScript is disabled for your browser. Some features of this site may not work without it.
Tout DSpace
  • Communautés & Collections
  • Par date de publication
  • Auteurs
  • Titres
  • Sujets

Statins and outcome after hospitalization for COPD exacerbation: A prospective study

Thumbnail
Auteur
Bartziokas, K.; Papaioannou, A. I.; Minas, M.; Kostikas, K.; Banya, W.; Daniil, Z. D.; Haniotou, A.; Gourgoulianis, K. I.
Date
2011
DOI
10.1016/j.pupt.2011.06.003
Sujet
COPD
Statins
Cardiovascular comorbidities
Mortality
exacerbations
Health-related quality of life
OBSTRUCTIVE PULMONARY-DISEASE
COA REDUCTASE INHIBITORS
QUALITY-OF-LIFE
SYSTEMIC INFLAMMATION
INCREASED RISK
LUNG-FUNCTION
HEALTH-STATUS
MORTALITY
MORBIDITY
COMORBIDITIES
Pharmacology & Pharmacy
Respiratory System
Afficher la notice complète
Résumé
Background: Retrospective studies have shown that the use of statins is associated with reduced mortality and decreased hospitalizations from COPD, but data from prospective studies are lacking. Methods: We followed-up prospectively 245 patients admitted to hospital for exacerbations of COPD (ECOPD) with monthly evaluations for one year. The role of statins on outcomes was evaluated by Cox regression analysis after proper adjustments for age, gender, BMI, current smoking status, Charlson comorbidity index and COPD stage. Health-related quality of life (HRQoL) was evaluated by Saint George's Respiratory Questionnaire. Results: There was no effect of statins on either 30-day or 1-year mortality. Patients receiving statins presented a lower total number of ECOPD during the 1-year follow up (2.1 +/- 2.7 vs. 2.8 +/- 3.2 ECOPD/patient respectively, p = 0.037). After proper adjustments, the use of statins was associated with a lower risk for ECOPD [HR: 0.656 (95% CI: 0.454-0.946)] and severe ECOPD [HR: 0.608 (95%CI: 0.381-0.972)]. The group of statins presented better improvement in HRQoL at 2, 6 and 12 months (p < 0.001). Conclusions: The use of statins in patients hospitalized for ECOPD was associated with a lower risk for subsequent ECOPD and severe ECOPD and improved HRQoL These data support a possible beneficial role for these agents in COPD. (C) 2011 Elsevier Ltd. All rights reserved.
URI
http://hdl.handle.net/11615/26184
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19743]
htmlmap 

 

Parcourir

Tout DSpaceCommunautés & CollectionsPar date de publicationAuteursTitresSujetsCette collectionPar date de publicationAuteursTitresSujets

Mon compte

Ouvrir une sessionS'inscrire
Help Contact
DepositionAboutHelpContactez-nous
Choose LanguageTout DSpace
EnglishΕλληνικά
htmlmap